Morgan Stanley downgraded Fractyl Health (GUTS) to Equal Weight from Overweight with a price target of $2, down from $8. In the randomized REMAIN-1 midpoint cohort at six months, Revita patients experienced 4.5% weight regain, which fell short of expectations and raises questions, the analyst tells investors. While the firm continues to believe success in the pivotal study is possible, it is taking a more cautious view and moving to the sidelines.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Advances Revita for Post-GLP-1 Weight Maintenance
- Fractyl Health announces results from trial evaluating Revita
- Biotech Alert: Searches spiking for these stocks today
- Fractyl Health price target lowered to $8 from $10 at Morgan Stanley
- Fractyl Health Appoints New Chief Financial Officer